Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma.
E. Lou
No relevant relationships to disclose
D. A. Reardon
Consultant or Advisory Role - Roche/Genentech; Schering-Plough
Honoraria - Roche/Genentech; Schering-Plough
K. Peters
No relevant relationships to disclose
A. Desjardins
No relevant relationships to disclose
J. E. Herndon
No relevant relationships to disclose
A. D. Coan
No relevant relationships to disclose
S. G. Turner
No relevant relationships to disclose
A. L. Sumrall
No relevant relationships to disclose
L. Bailey
No relevant relationships to disclose
H. S. Friedman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
J. J. Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech